APA (7th ed.) Citation

Bouvier, A., Hamel, J., Delaunay, J., Delabesse, E., Dumas, P., Ledoux, M., . . . Caillot, D. (2021). Molecular classification and prognosis in younger adults with acute myeloid leukemia and intermediate‐risk cytogenetics treated or not by gemtuzumab ozogamycin: Final results of the GOELAMS/FILO acute myeloid leukemia 2006‐intermediate‐risk trial. European Journal of Haematology, 107(1), 111. https://doi.org/10.1111/ejh.13626

Chicago Style (17th ed.) Citation

Bouvier, Anne, et al. "Molecular Classification and Prognosis in Younger Adults with Acute Myeloid Leukemia and Intermediate‐risk Cytogenetics Treated or Not by Gemtuzumab Ozogamycin: Final Results of the GOELAMS/FILO Acute Myeloid Leukemia 2006‐intermediate‐risk Trial." European Journal of Haematology 107, no. 1 (2021): 111. https://doi.org/10.1111/ejh.13626.

MLA (9th ed.) Citation

Bouvier, Anne, et al. "Molecular Classification and Prognosis in Younger Adults with Acute Myeloid Leukemia and Intermediate‐risk Cytogenetics Treated or Not by Gemtuzumab Ozogamycin: Final Results of the GOELAMS/FILO Acute Myeloid Leukemia 2006‐intermediate‐risk Trial." European Journal of Haematology, vol. 107, no. 1, 2021, p. 111, https://doi.org/10.1111/ejh.13626.